Emcure Pharmaceuticals Q1 Results Revenue ₹1,815.14 Crores & Net Income ₹144.08 Crores

Emcure Pharmaceuticals showed a large drop in its financial performance compared to the previous quarter in the first quarter of 2024. Their total revenue was ₹1,815.14 crores, which is a huge 72.74% decrease from the ₹5,985.81 crores it earned in March 2023. This drop in revenue affected almost every part of the company's finances.

Emcure Pharmaceuticals’ expenses also fell sharply. Selling, general, and administrative expenses were reduced by 81.69%, from ₹1,605.41 crores to ₹350.40 crores. Depreciation and amortization costs dropped by 70.04%, and other operating expenses decreased by 51.58%. Overall, total operating expenses went down by 72.66%.

Despite these reductions in costs, Emcure Pharmaceuticals’ operating income fell by 73.25%, from ₹915.25 crores to ₹242.73 crores. Net income before taxes decreased by 71.48%, and net income dropped by 71.08%. The earnings per share (EPS), a measure of profit per share, fell by nearly 70%. These results indicate that while Emcure managed to reduce its costs significantly, its revenue and profits have declined sharply, leading to a challenging financial period.

Here is a summary of Emcure Pharmaceuticals' Q1 financial results for June 2024, compared to March 2023:

Source: Here 

For More Q1 Results check our Twitter Page

Visit our website for more Q1 results

Emcure Pharmaceuticals Q1 Results

EMCURE Pharmaceuticals Reported their financial results for the quarter ending June 30, 2024. The company earned a total income of ₹10,027.99 million, which is higher than the ₹9,367.04 million reported for the previous quarter. Their revenue from operations increased to ₹9,702.93 million from ₹9,025.46 million, and other income also rose to ₹325.06 million from ₹341.58 million.

Emcure Pharmaceuticals’ total expenses for the quarter were ₹9,477.51 million, up from ₹8,919.16 million last quarter. Key expenses included costs for materials and stock-in-trade, employee benefits, depreciation, and finance costs. The company’s profit before tax was ₹550.48 million, which was a bit higher compared to ₹354.73 million in the previous quarter. 

Emcure Pharmaceuticals’ after accounting for taxes and exceptional items, the profit for the quarter stood at ₹404.46 million, an increase from ₹289.78 million last quarter. The earnings per share (EPS) were ₹2.23, compared to ₹1.60 in the previous quarter. The company’s total comprehensive income, which includes all gains and losses, was ₹402.22 million, up from ₹237.82 million.

Emcure Pharmaceutical Financial Overview

Emcure Pharmaceuticals’ table provides financial information about the company. Their market capitalization, or total value of its shares, is ₹26,259 Crores. The current price of one share is ₹1,389. The highest price in a specific period was ₹1,409, and the lowest was ₹1,225. The stock's price-to-earnings (P/E) ratio is 52.2, indicating how much investors are willing to pay per unit of earnings.

Here’s a summary of the results:

Emcure Pharmaceuticals Financial Performance 

Here's the market data in table format:

About Emcure Pharmaceuticals

Emcure Pharmaceuticals is a global company that develops, makes, and sells a wide variety of medicines. They focus on major health areas like gynecology, cardiology, blood disorders, cancer, respiratory issues, brain and nervous system problems, and HIV. The company is known for its strong presence in these fields and has introduced six biologic drugs in various markets. Emcure is a leader in three of these biologics in India.

As of September 30, 2023, Emcure has over 350 brands in India, five research and development centers, and 13 manufacturing facilities. They operate in more than 70 countries, showing their wide international reach. Their manufacturing process is well-managed through their API facilities, which helps them control production and ensure high quality.

Founded in the early 1980s, Emcure is one of the top 13 pharmaceutical companies in India and employs over 10,000 people. The company's Managing Director and CEO, Satish Ramanlal Mehta, emphasizes their focus on creating unique products through research and development. Their goal is to offer affordable, high-quality healthcare solutions and to make a positive impact on global health.